Annette Von Delft

Oxford, ENG OX37FZ, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 22 publications

Discovery of orally bioavailable Zika and West Nile Virus antiviral compounds targeting the NS2B-NS3 protease.

Discovery of orally bioavailable Zika and West Nile Virus antiviral compounds targeting the NS2B-NS3 protease.

Journal: bioRxiv : the preprint server for biology

Published: July 16, 2025

Open-science discovery of DNDI-6510, a compound that addresses genotoxic and metabolic liabilities of the COVID Moonshot SARS-CoV-2 Mpro lead inhibitor.

Open-science discovery of DNDI-6510, a compound that addresses genotoxic and metabolic liabilities of the COVID Moonshot SARS-CoV-2 Mpro lead inhibitor.

Journal: bioRxiv : the preprint server for biology

Published: July 16, 2025

Combined crystallographic fragment screening and deep mutational scanning enable discovery of Zika virus NS2B-NS3 protease inhibitors.

Combined crystallographic fragment screening and deep mutational scanning enable discovery of Zika virus NS2B-NS3 protease inhibitors.

Journal: Nature communications

Published: January 21, 2025

Assessment of repurposed compounds against coronaviruses highlights the antiviral broad-spectrum activity of host-targeting iminosugars and confirms the activity of potent directly acting antivirals.

Assessment of repurposed compounds against coronaviruses highlights the antiviral broad-spectrum activity of host-targeting iminosugars and confirms the activity of potent directly acting antivirals.

Journal: Antiviral research

Published: October 22, 2024

Identification and characterization of human KALRN mRNA and Kalirin protein isoforms.

Identification and characterization of human KALRN mRNA and Kalirin protein isoforms.

Journal: Cerebral cortex (New York, N.Y. : 1991)

Published: June 03, 2024

An Update on SARS-CoV-2 Clinical Trial Results-What We Can Learn for the Next Pandemic.

An Update on SARS-CoV-2 Clinical Trial Results-What We Can Learn for the Next Pandemic.

Journal: International journal of molecular sciences

Published: November 28, 2023

Open science discovery of potent noncovalent SARS-CoV-2 main protease inhibitors.

Open science discovery of potent noncovalent SARS-CoV-2 main protease inhibitors.

Journal: Science (New York, N.Y.)

Published: November 09, 2023

Accelerating antiviral drug discovery: lessons from COVID-19.

Accelerating antiviral drug discovery: lessons from COVID-19.

Journal: Nature reviews. Drug discovery

Published: April 04, 2023

Protocol paper: a multi-center, double-blinded, randomized, 6-month, placebo-controlled study followed by 12-month open label extension to evaluate the safety and efficacy of Saracatinib in Fibrodysplasia Ossificans Progressiva (STOPFOP).

Protocol paper: a multi-center, double-blinded, randomized, 6-month, placebo-controlled study followed by 12-month open label extension to evaluate the safety and efficacy of Saracatinib in Fibrodysplasia Ossificans Progressiva (STOPFOP).

Journal: BMC musculoskeletal disorders

Published: April 22, 2022

Kalirin as a Novel Treatment Target for Cognitive Dysfunction in Schizophrenia.

Kalirin as a Novel Treatment Target for Cognitive Dysfunction in Schizophrenia.

Journal: CNS drugs

Published: November 21, 2021

A white-knuckle ride of open COVID drug discovery.

A white-knuckle ride of open COVID drug discovery.

Journal: Nature

Published: June 15, 2021

Incoming HIV virion-derived Gag Spacer Peptide 2 (p1) is a target of effective CD8+ T cell antiviral responses.

Incoming HIV virion-derived Gag Spacer Peptide 2 (p1) is a target of effective CD8+ T cell antiviral responses.

Journal: Cell reports

Published: October 06, 2020

Showing 1-12 of 22

Last Updated: 09/26/2026